iBio, Inc.

Contributing Author

Recent Articles by iBio, Inc.

Aug-04	iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer IBIO GlobeNewswire
Jul-01	iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study IBIO GlobeNewswire
Jun-02	iBio to Participate in Upcoming Healthcare Investor Conferences IBIO -6.88% GlobeNewswire
Jun-02	iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity IBIO -6.88% GlobeNewswire
May-12	iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update IBIO GlobeNewswire
May-08	iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors IBIO GlobeNewswire
Apr-08	iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia IBIO +6.16% GlobeNewswire
Mar-16	iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) IBIO GlobeNewswire
Mar-09	iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss IBIO GlobeNewswire
Feb-24	iBio to Participate in Upcoming Investor Conferences IBIO GlobeNewswire
Feb-10	iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update IBIO -5.81% GlobeNewswire
Jan-09	iBio Announces $26 Million Private Placement IBIO +14.89% GlobeNewswire
Nov-24	iBio to Participate in the 8th Annual Evercore Healthcare Conference IBIO +5.71% IBIO +5.41% GlobeNewswire
Nov-12	iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update IBIO IBIO -8.00% GlobeNewswire
Oct-30	iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance IBIO GlobeNewswire
Oct-23	iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference IBIO -8.63% GlobeNewswire
Oct-21	iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek and PEGS Europe 2025 IBIO +24.30% GlobeNewswire
Sep-05	iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update IBIO GlobeNewswire
Aug-25	iBio Announces Closing of $50 Million Public Offering IBIO +6.93% GlobeNewswire
Aug-19	iBio Announces Pricing of $50 Million Public Offering IBIO GlobeNewswire
Aug-18	iBio Announces Proposed Public Offering IBIO GlobeNewswire
Jun-24	iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results IBIO GlobeNewswire
Jun-23	iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call IBIO -7.60% GlobeNewswire
Jun-16	iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment IBIO -5.83% GlobeNewswire
May-05	iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model IBIO GlobeNewswire
May-02	iBio Reports Fiscal Third Quarter 2025 Financial Results IBIO GlobeNewswire

iBio, Inc.

Recent Articles by iBio, Inc.

Upgrade your Finviz experience